Nearly one-quarter of adults with metabolic dysfunction-associated steatotic liver disease and cirrhosis presented before age ...

Living to 100 is no longer an abstract rarity, yet it remains uncommon enough to raise a persistent question. Do people who ...

Patients should be selected for treatment with Enhertu in combination with pertuzumab based on confirmed HER2-positive status or HER2 gene amplification (IHC 3+ or ISH+).

Background Hepatocellular carcinoma (HCC) is a leading cause of cancer mortality with limited therapeutic options. Despite ...